Evidence map›Paper›PMID 41507612›Full record

ArticleMikrochimica acta2026

Software assisted personalized transduction platform for serum biomarker detection based on electrochemically engineered Cr-MOF - graphene oxide nanohybrid.

Divya, Shubhangi, Riddhi Dubey, Ratul Paul, Ankur Singh, Pranjal Chandra

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

DivyaLaboratory of Bio-Physio Sensors and Nanobioengineering, School of Biochemical Engineering, Indian Institute of Technology (BHU), Varanasi, Varanasi, 221005, Uttar Pradesh, India.
ShubhangiLaboratory of Bio-Physio Sensors and Nanobioengineering, School of Biochemical Engineering, Indian Institute of Technology (BHU), Varanasi, Varanasi, 221005, Uttar Pradesh, India.
Riddhi DubeyLaboratory of Bio-Physio Sensors and Nanobioengineering, School of Biochemical Engineering, Indian Institute of Technology (BHU), Varanasi, Varanasi, 221005, Uttar Pradesh, India.
Ratul PaulLaboratory of Bio-Physio Sensors and Nanobioengineering, School of Biochemical Engineering, Indian Institute of Technology (BHU), Varanasi, Varanasi, 221005, Uttar Pradesh, India.
Ankur SinghLaboratory of Bio-Physio Sensors and Nanobioengineering, School of Biochemical Engineering, Indian Institute of Technology (BHU), Varanasi, Varanasi, 221005, Uttar Pradesh, India.
Pranjal ChandraLaboratory of Bio-Physio Sensors and Nanobioengineering, School of Biochemical Engineering, Indian Institute of Technology (BHU), Varanasi, Varanasi, 221005, Uttar Pradesh, India. pranjal.bce@iitbhu.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Incorporation of versatile hybrid frameworks with high surface area 2D materials can be an interesting approach for the development of sensitive biosensing platforms. A single step electrodeposition of chromium metal organic framework (Cr-MOF) and its nanoengineering through graphene oxide (GO) incorporation has been attempted in this study for the immunosensing of alkaline phosphatase (ALP). ALP being a crucial biomarker with its close association to health abnormalities including liver disease, bone disorder, and kidney damage can be an important area for diagnosis. Here, Cr-MOF has been incorporated with GO for the bioconjugation of Anti-ALP to facilitate selective binding and detection of ALP. The developed probe has been thoroughly characterized through various physical and electrochemical techniques for the confirmation of synthesis and binding events of the final probe with the target analyte. This unveiled good analytical capability with a wide linear dynamic range from 50 U/L to 1000 U/L and a detection limit of 2.64 U/L, covering the clinically relevant range. This platform has also been tested against categories of potential interferants ranging from ions to biomolecules, along with real sample testing in serum samples with a proven recovery between 86 and 98%. Further, the developed probe was integrated with software for data analysis and providing a user-friendly approach for ALP detection. This study can further be improvised to deploy in the primary healthcare centres/remote areas for more affordable diagnosis.

Indexed as

Alkaline PhosphataseBiosensing TechniquesElectrochemical TechniquesGraphiteBiomarkersChromiumHumansImmunoassayLimit of DetectionAlkaline PhosphataseBiomarkersChromiumgraphene oxideGraphiteAlkaline phosphataseCr MOFDifferential pulse voltammetryElectrodepositionHealth monitoringImmunosensorModified glassy carbon electrode

Identifiers

PMID41507612

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.